»
INDUSTRY NEWS
»
better resolution, higher effi ciency, easy method transferability, and cost savings from reduced solvent consumption. The Kinetex 2.6-µm F5 provides performance comparable to sub-2-µm particles on both standard HPLC and UHPLC systems. The 1.7-µm column delivers 20% greater effi ciencies than fully porous sub-2-µm products.
“Our company truly values the customers’ voice and working beyond the status quo,” explains Simon Lomas, brand manager for Phenomenex. “These new Kinetex F5 columns are the result of years of research, development, and customer input. With better, more accurate, and higher performance products like the Kinetex core-shell F5, scientists can continue to push the current limits of separation science.
Phenomenex is a global technology leader committed to developing novel analytical chemistry solutions that solve the separation and purifi cation challenges of researchers in industrial, clinical research, government, and academic laboratories. From drug discovery and pharmaceutical development to food safety and environmental analysis, Phenomenex chromatography solutions accelerate science and help researchers improve global health and well-being. For more information on Phenomenex, visit
www.phenomenex.com or follow the company on Twitter @Phenomenex.
Keystone Folding Box Co. Launches Ecoslide-RX 2.0 Compliance Package
Walmart First to Adopt Next-Generation Compliance Package
Walmart has announced plans to incorporate the next generation of Keystone Folding Box Company’s Ecoslide-RX compliance package into its pharmacies nationwide beginning in 2015. The new Ecoslide-RX 2.0 off ers a host of upgraded features that enhance user-friendliness, including redesigned lock/unlock functionality and enhanced graphics providing more dynamic user instructions.
The package passed Consumer Product Safety Commission (CPSC) protocol testing for child resistance and once again received the highest rating, F=1. In addition to demonstrating a high level of senior friendliness, Ecoslide RX 2.0 was also reported by patients to be “easy to open” in consumer testing.
“With Ecoslide RX 2.0, the overall consumer experience has been improved: the opening procedure of the new package is more intuitive, and minimal eff ort is required to unlock the package.
Enhanced
graphics present operating instructions that are easily understood—a benefi t particularly to seniors who, understandably, comprise a signifi cant percentage of prescription medication users,” explained Ward Smith, Director of Marketing at Keystone Folding Box Company. “Major pharmaceutical manufacturers are expressing strong interest in this package based on the overall customer experience.”
Compliance packaging helps prompt patients to take medications correctly. Many compliance packages off er day-of-the-week calendarization for each individual dose, which has been shown to signifi cantly increase patients’ likelihood to adhere to medication
70 | | January/February 2015
regimens. Keystone’s latest package design is also more environmentally sustainable than competing packages, hence its Ecoslide moniker.
In 2011, a published peer-reviewed study of over 300 000 Walmart pharmacy patients during a 2-year period concluded that compliance, or adherence, packaging improved adherence and persistency.
The
same Walmart study showed a signifi cant ROI for the incremental cost of the compliance package over traditional bottles.
Ecoslide-RX 2.0 works for prescription products, physicians’ samples, and clinical trial materials.
it allows for large, easy-to-read type on all sides conducive to clear, simple opening instructions, and off ers a more reliable locking mechanism. The compliance pack also is easy to stack in medicine cabinets and convenient to transport.
risk of contamination from dropping, spilling, or moisture, and can be equipped with useful weekly calendars/reminders that help consumers keep track of their medications.
Camargo Launches New Brand at GPhA as 505(b)(2) Development Continues Upward Trend
Camargo Pharmaceutical Services, a leading drug development
organization specializing in the 505(b)(2) approval pathway, will reveal its new brand at the Generic Pharmaceutical Association (GPhA) Annual Meeting. The new brand comes as 505(b)(2) is fast becoming the preferred approval pathway for companies looking to reposition existing products or expand portfolios with diff erentiated products.
“The number of 505(b)(2) approvals has increased steadily in the past few years, and is more relevant than ever given current market constraints, such as the generics cliff ,” said Ken Phelps, president and CEO of Camargo. “To date, our team has guided more than 200 FDA approvals and now leads the largest percentage of 505(b)(2) submissions of any team submitting to the FDA,” said Phelps. “The new brand encapsulates what we do best: identify and develop viable products.”
In addition to the brand launch, Phelps said Camargo will be discussing the recently organized 505(b)(2) Forum, of which Camargo is a founding member.
The 505(b)(2) Forum was organized by product developers and service providers interested in improving best practices across the 505(b)(2) development process. With 4 events scheduled for 2015, participating companies and attendees will discuss the 505(b)(2) regulatory approval pathway and how this pathway can provide a cost eff ective and comprehensive solution for developing viable products.
For an advanced look at the new brand and to learn more about how Camargo guides fast and cost-eff ective 505(b)(2) development from concept through commercialization, visit
http://www.camargopharma. com/505B2globalexperts/
index.html.
It is superior to traditional vials because
Blister packages have less
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76